Lucentis (ranibizumab; Novartis) has been approved for the treatment of wet age-related macular degeneration (AMD) in Japan, Novartis has announced.
Lucentis (ranibizumab; Novartis) has been approved for the treatment of wet age-related macular degeneration (AMD) in Japan, Novartis has announced.
The application for approval in Japan was supported by a clinical trial demonstrating the efficacy of the anti-vascular endothelial growth factor (anti-VEGF) therapy. The approval comes simultaneously with three other Novartis drug approvals in Japan: Tasigna, for cancer, Xolair for asthma and Co-Dio for high blood pressure.
Lucentis has been approved in Europe since February 2007.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.